Novartis - Vertex Drug Discovery Collaboration on Kinases to be Presented at Pharma & Biotech Licensing Conference on June 4-5 in Philadelphia

Apr 18, 2001, 01:00 ET from Strategic Research Institute

    PHILADELPHIA, April 18 /PRNewswire/ -- Many deals are to be presented at
 the 5th International Pharma & Biotech Licensing & Deal-Making Summit,
 including "Target Family Deal Making: The Vertex - Novartis Collaboration,"
 presented by Robert Mashal, M.D., of Vertex Pharmaceuticals, announces
 Strategic Research Institute.
     In 2000, Vertex and Novartis entered into a broad-based drug discovery
 collaboration on kinases.  Over the course of the collaboration, Novartis
 could, subject to milestones and other conditions, make pre-commercial
 payments to Vertex of $800 million, based on the successful discovery and full
 development of eight compounds.  The size and scope (> 500 targets) reflect
 Vertex's approach to drug discovery.  The deal's terms, structure, goals, and
 current status as well as future directions in discovery deal-making at Vertex
 will be discussed.
     This is the first ever conference to feature such a breadth of deal talks
 across such a gamut of therapeutic classes and enabling technologies.  This
 conference series is a major business development and networking extravaganza
 for the industry and biotech/biopharmaceutical investment community.
 
     Other featured deals include:
     * The CuraGen and Bayer AG Aliance - Landmark Drug Discovery, Development
       and Pharmacogenomic Partnership
     * Genome Sciences - Cambridge Antibody Technologies Collaboration in
       Immunotherapy
     * Elan Corporation: Spreading Risk Across Early-Stage Collaborations
       Through Structured Financing Arrangements
 
     Other important deals are featured as well during the course of the
 conference.
     On the investment side, talks on prospective deals over the ensuing 12
 months and an analysis of biotech and genomic valuations are planned.
 
     They are:
     * Are Current Biotechnology & Genomic Valuations Justified?, by Mehta
       Partners LLC
     * What Kinds of Deals Will We Likely See in Second Half 2001 -- First Half
       2001, presented by Legg Mason Wood Walker.
 
     A reception and networking dinner are planned after the first day to
 foster interaction among speakers and attendees.
     To register/request the agenda, please contact Sem Sepulveda at
 ssepulveda@srinstitute.com, or Sumeet Hora at shora@srinstitute.com or
 212-967-0095, extension 261.
     Contact Mark Alexay for information on sponsoring a function or
 exhibiting.  200+ pharma, biotech, and drug delivery business development,
 technology assessment/acquisition, licensing, as well as the investment
 community attended the April 2000 meeting.  Prime space is still available for
 exhibiting as are sponsorable functions for a much greater splash.
 
 

SOURCE Strategic Research Institute
    PHILADELPHIA, April 18 /PRNewswire/ -- Many deals are to be presented at
 the 5th International Pharma & Biotech Licensing & Deal-Making Summit,
 including "Target Family Deal Making: The Vertex - Novartis Collaboration,"
 presented by Robert Mashal, M.D., of Vertex Pharmaceuticals, announces
 Strategic Research Institute.
     In 2000, Vertex and Novartis entered into a broad-based drug discovery
 collaboration on kinases.  Over the course of the collaboration, Novartis
 could, subject to milestones and other conditions, make pre-commercial
 payments to Vertex of $800 million, based on the successful discovery and full
 development of eight compounds.  The size and scope (> 500 targets) reflect
 Vertex's approach to drug discovery.  The deal's terms, structure, goals, and
 current status as well as future directions in discovery deal-making at Vertex
 will be discussed.
     This is the first ever conference to feature such a breadth of deal talks
 across such a gamut of therapeutic classes and enabling technologies.  This
 conference series is a major business development and networking extravaganza
 for the industry and biotech/biopharmaceutical investment community.
 
     Other featured deals include:
     * The CuraGen and Bayer AG Aliance - Landmark Drug Discovery, Development
       and Pharmacogenomic Partnership
     * Genome Sciences - Cambridge Antibody Technologies Collaboration in
       Immunotherapy
     * Elan Corporation: Spreading Risk Across Early-Stage Collaborations
       Through Structured Financing Arrangements
 
     Other important deals are featured as well during the course of the
 conference.
     On the investment side, talks on prospective deals over the ensuing 12
 months and an analysis of biotech and genomic valuations are planned.
 
     They are:
     * Are Current Biotechnology & Genomic Valuations Justified?, by Mehta
       Partners LLC
     * What Kinds of Deals Will We Likely See in Second Half 2001 -- First Half
       2001, presented by Legg Mason Wood Walker.
 
     A reception and networking dinner are planned after the first day to
 foster interaction among speakers and attendees.
     To register/request the agenda, please contact Sem Sepulveda at
 ssepulveda@srinstitute.com, or Sumeet Hora at shora@srinstitute.com or
 212-967-0095, extension 261.
     Contact Mark Alexay for information on sponsoring a function or
 exhibiting.  200+ pharma, biotech, and drug delivery business development,
 technology assessment/acquisition, licensing, as well as the investment
 community attended the April 2000 meeting.  Prime space is still available for
 exhibiting as are sponsorable functions for a much greater splash.
 
 SOURCE  Strategic Research Institute